CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02
|
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. |
Celgene Corporation (the Company) today announced organizational
changes. Jacqualyn Fouse, PhD, has announced her retirement as an
officer of the Company effective June 30, 2017 and will not stand
for reelection to the Board of Directors at the upcoming Annual
Meeting in June. Additionally, effective April 1, 2017:
- Scott Smith, President, Global Inflammation Immunology, will
be promoted to President and Chief Operating Officer. - Terrie Curran will be promoted to President, Global
Inflammation Immunology.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS. |
(d) Exhibit 99.1 Press Release dated February 23, 2017.
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. CELGENE CORPORATION (NASDAQ:CELG) Recent Trading Information
CELGENE CORPORATION (NASDAQ:CELG) closed its last trading session up +0.19 at 119.46 with 4,373,539 shares trading hands.